Inflammatory Bowel Diseases

Papers
(The TQCC of Inflammatory Bowel Diseases is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS191
THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS77
Is it a Flare? Acute Appendicitis in Ulcerative Colitis Patient Found on Routine Screening Colonoscopy75
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease67
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC63
DEPRESSION MAY BE A STRONGER UNIQUE PREDICTOR OF FATIGUE THAN SELF-REPORTED IBD DISEASE ACTIVITY61
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS60
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD58
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS52
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY51
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS51
Improving Brain–Gut Studies in Crohn’s Disease: Methodological Considerations50
Gut Feelings Matter: The Unresolved Questions of Irritable Bowel Syndrome-Like Symptoms in Inflammatory Bowel Disease in Remission50
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION48
Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes48
Phosphoproteomics Reveals Novel Insights into the Pathogenesis and Identifies New Therapeutic Kinase Targets of Ulcerative Colitis45
COMPARATIVE RISK OF LYMPHOMA IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH THIOPURINES AND/OR ANTI-TNF AGENTS: AN UMBRELLA REVIEW OF META-ANALYSES44
AN INTEGRATED MULTI-OMIC APPROACH REVEALS A SHARED SIGNATURE OF IMMUNE ACTIVATION AND METABOLIC COLLAPSE IN ULCERATIVE COLITIS AND RHEUMATOID ARTHRITIS44
Author’s Response to Comment on “Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease”43
COMPARATIVE PERIOPERATIVE OUTCOMES OF LUMBAR SPINAL SURGERY IN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS43
Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study42
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry41
Prior Appendectomy Is Associated With a Milder Clinical Course in Crohn’s Disease: A Nationwide Population-based Cohort Study41
INFLAMMATORY BOWEL DISEASE IN YOUTH UNDER 20 FROM 1990-2019: A GLOBAL PERSPECTIVE ON REGIONAL AND NATIONAL VARIATIONS FROM THE GBD 2019 ANALYSIS40
ROLE OF EPITHELIAL LTA4H-LTB4 SIGNALING IN RESOLUTION OF COLONIC MUCOSAL WOUNDS40
Following Through: The Impact of Culinary Medicine on Mediterranean Diet Uptake in Inflammatory Bowel Disease40
DEVELOPMENT OF A NEXT GENERATION ENGINEERED LIVE MICROBIOME BIOTHERAPEUTIC, E COLI NISSLE 1917-TTR, FOR ULCERATIVE COLITIS40
TERTIARY LYMPHOID STRUCTURES (TLS) EXPANSION PARALLELS ILEITIS PROGRESSION IN TNFΔARE MICE, REQUIRES β7 INTEGRIN AND CCR7, AND DECREASES IN SIZE AFTER GLUCOCORTICOID ADMINISTRATION39
EPIGENETIC REPRESSORS MAINTAIN TREG STABILITY IN A FOXP3-INDEPENDENT MANNER38
EVALUATING POUCH RELATED OUTCOMES WITH GLUCAGON LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS IN PATIENTS WITH ILEAL POUCH ANAL ANASTOMOSIS—A DATABASE STUDY IN THE UNITED STATES38
Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey37
Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases37
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis36
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS35
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis35
The Prevalence of Chronic Opioid Use in Patients With Inflammatory Bowel Disease: A Nationwide Danish Register-Based Study Over a 25-Year Period of Time33
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease33
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED 33
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OL32
Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients: Systematic Review With Meta-Analysis31
Vitamin D3 andLactobacillus rhamnosusGG/p40 Synergize to Protect Mice From Colitis by Promoting Vitamin D Receptor Expression and Epithelial Proliferation31
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN31
Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease30
OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study30
DO PROVIDERS FAIL TO RECOGNIZE ANXIETY IN SOCIALLY VULNERABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE?29
Correction to: Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response29
AN OBSERVATIONAL STUDY DEMONSTARTING THE MEASUREMENT, CHARACTERIZATION AND VALIDATION OF EXPRESSIONS OF CALPROTECTIN IN HUMAN SWEAT THROUGH A SWEAT WEARABLE29
INCORPORATION OF RISK ASSESSMENT TOOL IMPACTS PATIENT AND GASTROENTEROLOGIST CONFIDENCE AND TREATMENT DECISION MAKING IN BIONAIVE CROHN’S DISEASE29
Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study29
POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON28
A RARE PRESENTATION OF ULCERATIVE COLITIS WITH ABSCESS FORMATION28
EVIDENCE OF PROTEASE-MEDIATED PRO-NOCICEPTIVE EFFECTS IN INFLAMMATORY BOWEL DISEASE PATIENTS28
PEDIATRIC PATIENTS WITH CORMORBID DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS AND INFLAMMATORY BOWEL DISEASE28
SWEET AND SALTY: SWEET SYNDROME AS THE INITIAL PRESENTATION OF NEWLY DIAGNOSED ULCERATIVE COLITIS28
Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Call to Action to Improve Patient Care28
ASSOCIATED COST DIFFERENCES OF SWITCHING BETWEEN INFLIXIMAB PRODUCTS28
REGIONAL AND RACIAL DISPARITIES IN ULCERATIVE COLITIS AND CHOLANGIOCARCINOMA RELATED MORTALITY IN THE UNITED STATES AND TEXAS: A 21 YEAR OBSERVATIONAL STUDY28
HUMAN β-DEFENSIN 2 ISOFORMS EXPRESSION ON PEDIATRIC IBD27
Response to the Letter to the Editor: “AI-Assisted IBD Severity Classification: A Critical Perspective on Current Evidence and Next Steps”27
FREE AIR FROM WHERE? SPONTANEOUS PNEUMOMEDIASTINUM AND SUBCUTANEOUS EMPHYSEMA IN A PATIENT WITH ULCERATIVE COLITIS IN THE ABSENCE OF COLONIC OR ESOPHAGEAL PERFORATION27
Letter: Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis—Authors’ Reply27
TNF IS REQUIRED FOR SPONTANEOUS INNATE COLITIS IN MICE LACKING ADAPTIVE IMMUNITY26
The prevalence of abdominal computed tomography imaging findings in patients with inflammatory bowel disease who present to the emergency department: a systematic review and meta-analysis26
IMPACT OF PATIENT DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND SOCIAL DETERMINANTS OF HEALTH ON ADVANCED THERAPY MEDICATION ADHERENCE AND PERSISTENCE IN ULCERATIVE COLITIS ACROSS UNITED STATES PAYER TY26
HIGH COPY NUMBER POLYMORPHISMS OF ALPHA DEFENSIN 1-3 ARE ASSOCIATED WITH THERAPEUTIC RESPONSIVENESS IN INFLAMMATORY BOWEL DISEASE26
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device26
INFECTIOUS COMPLICATIONS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS26
Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity26
ULCERATIVE COLITIS-DERIVED INTESTINAL EPITHELIAL CELLS ARE PROTECTED FROM CELL DEATH BY THE IMMUNE MEDIATORS RELEASED FROM RESTING AND ACTIVATED SYSTEMIC T CELLS26
EFFICACY AND FEASIBILITY OF THE KOREAN CROHN’S DISEASE EXCLUSION DIET (K-CDED) IN PEDIATRIC CROHN’S DISEASE25
Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials25
The Value of a Dedicated IBD Flare Clinic to Effectively Manage Exacerbations of Inflammatory Bowel Disease: The Edinburgh IBD Unit25
METABOLITE MIMICRY REVEALS BUTYRATE ANALOG WITH SELECTIVE PROTECTIVE FUNCTIONS IN THE INTESTINAL MUCOSA25
Intestinal Ultrasound Measures are Strongly Correlated With Small Bowel Endoscopic Lewis Score in Active Crohn’s Disease25
A CASE SERIES: FEASIBILITY AND SAFETY OF ENDOSCOPIC RESECTION FOR COLORECTAL DYSPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE25
Epidemiology of Inflammatory Bowel Disease in a Cohort of US Black Women25
Rectal and Rectosigmoid Endoscopy to Assess Endoscopic and Histological Remission in Ulcerative Colitis: A Prospective Study24
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease24
Past But Not Forgotten: Innate Factors Affect the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease24
Childhood Socioeconomic Characteristics and Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study24
Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn’s Disease24
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study24
REPOGRAMING OF THE INTESTINAL IMMUNE CELL COMPARTMENT DEFINES THE RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN CROHNS DISEASE24
Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions24
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study23
Excessive Mitochondrial Fission Suppresses Mucosal Repair by Impairing Butyrate Metabolism in Colonocytes23
Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients23
The Norepinephrine-QseC Axis Aggravates F. nucleatum-associated Colitis Through Interkingdom Signaling23
Biological Ageing and the Risk of Inflammatory Bowel Disease: Exploring the Role of Lifestyle and Genetic Susceptibility in a Nationwide Prospective Study22
Challenges in IBD Research 2024: Novel Technologies22
MYO5B and the Polygenic Landscape of Very Early-Onset Inflammatory Bowel Disease in an Ethnically Diverse Population22
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials22
Lack of Efficacy of Concomitant 5-Aminosalicylic Acid With Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis22
AEROMONAS IMMUNE MODULATOR PROTEINS INTERACT WITH HOST LIPOCALIN-2 TO MEDIATE INFLAMMATION THROUGH BOTH HOST- AND MICROBIOME-SPECIFIC MECHANISMS22
Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease22
Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis22
2ʹ-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT322
The Time to Inflammatory Bowel Disease Diagnosis for Patients Presenting with Abdominal Symptoms in Primary Care and its Association with Emergency Hospital Admissions and Surgery: A Retrospective Coh22
EFFICACY AND SAFETY OF VEDOLIZUMAB AND TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF STEROID-REFRACTORY MICROSCOPIC COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS21
Potential Utility of Laser Speckle Contrast Imaging to Detect Early Microcirculatory Changes Associated With Erythema Nodosum in Crohn’s Disease: A Case Report21
PERIPHERAL BLOOD EXTRACELLULAR VESICLE LIPIDS AS BIOMARKERS FOR HUMAN INFLAMMATORY BOWEL DISEASE21
Association Between Maternal Infections in Pregnancy and the Risk of Inflammatory Bowel Disease in the Offspring: Findings From Two Scandinavian Birth Cohorts21
Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD21
THE IMPACT OF INFLAMMATORY BOWEL DISEASES ON THE OUTCOMES OF PATIENTS ADMITTED WITH ACUTE VIRAL HEPATITIS: A 2016-2019 NATIONWIDE ANALYSIS21
Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria21
Pro-inflammatory Cytokines Promote the Occurrence and Development of Colitis-associated Colorectal Cancer by Inhibiting miR-615-5p20
Use of Upadacitinib as Salvage Therapy for Ulcerative Colitis in Pregnancy: A Case Report20
Comment on: “The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis”20
Advancing Toward Transmural Healing in Pediatric Crohn’s Disease20
IBD Journal Editorial Fellowship: A Practical Guide for Future Fellows20
Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients20
ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND HIDRADENITIS SUPPURATIVA: A SINGLE-CENTER RETROSPECTIVE STUDY20
CLINICAL BENEFITS OF PROBIOTIC SUPPLEMENTATION IN INFLAMMATORY BOWEL DISEASE TREATMENT: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS20
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE20
The Clinical Interpretation of Cluster Trials20
Aeroallergen-related Diseases Predate the Diagnosis of Inflammatory Bowel Disease20
CYTOKINE MULTI-OMICS AND MACHINE LEARNING IDENTIFY MIP1ALPHA AS A NOVEL MEDIATOR IN INFLAMMATORY BOWEL DISEASE20
EFFICACY OF UPADACITINIB INDUCTION FOR PEDIATRIC IBD20
BEYOND THE BOWEL: A CASE OF SWEET SYNDROME COMPLICATING IBD20
Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up19
Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients With Ileal Pouch-Anal Anastomosis19
Impact of Inflammatory Bowel Disease on Patients’ Caregivers: Results From a French Survey19
Clinical outcomes in pregnancy after ileal pouch-anal anastomosis for ulcerative colitis19
Genome-Wide Aggregated Trans -Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease19
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Stu19
Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?19
Evaluating lleal Pouch Anal Anastomosis Function: Time to Expand Our ARM-amentarium19
The Importance of Treatment Timing and Positioning in IBD19
Disease reprogression following surgical resection in Crohn disease19
LOSS OF CGNL1 CONTRIBUTES TO VERY EARLY ONSET IBD18
SAFETY OF PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM A LARGE ADMINISTRATIVE COHORT18
Research Progress of Interleukin-27 in Inflammatory Bowel Disease18
Endoscopic Stenting in Crohn’s Disease-related Strictures: A Systematic Review and Meta-analysis of Outcomes18
How to Minimize Placebo Response and Remission Rates18
QUANTITATIVE SMALL BOWEL MOTILITY ASSESSMENT ON MAGNETIC RESONANCE ENTEROGRAPHY IN PEDIATRIC CROHN’S DISEASE: ASSOCIATIONS WITH CLINICAL PHENOTYPE AND SURGICAL OUTCOME18
Distinct Effects of Autologous Hematopoietic Stem Cell Transplantation on T Cell Composition and Profile in Refractory Crohn’s Disease18
Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series18
MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL U.S. COHORT18
Timing is Everything: Lessons Learned for Building Microbiome-Based Models in Pediatric Crohn’s Disease18
METABOLIC INFLAMMATION IN CROHN’S DISEASE: EFFECTS OF CARNITINE PAMITOYLTRANSFERASE ACTIVITY ON INFLAMMATORY SIGNALING IN THE INTESTINAL EPITHELIUM18
VENOUS THROMBOEMBOLISM AND INPATIENT OUTCOMES IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM THE NATIONWIDE INPATIENT SAMPLE18
Deep Dive Into MicroRNAs in Inflammatory Bowel Disease18
Coronary Artery Plaque Assessment by CT Angiogram in Inflammatory Bowel Disease18
Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis17
Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases17
IDENTIFICATION OF DISEASE SEVERITY DEFINITIONS FOR ULCERATIVE COLITIS AND CROHN’S DISEASE17
PRELIMINARY EVIDENCE FOR A RELATIONSHIP BETWEEN HEART RATE VARIABILITY AND FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)17
THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS17
Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis17
Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab17
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib17
HISTOPATHOLOGICAL CHARACTERIZATION OF A CHRONIC DSS-INDUCED MOUSE MODEL OF IBD WITH INTESTINAL FIBROSIS17
PRIMARY EOSINOPHILIC COLITIS WITH CONCOMITANT NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE – A DIAGNOSITIC CONUNDRUM17
CONFIDENCE IN REMISSION: A KEY CONTRIBUTOR IN DEVELOPING POST-TRAUMATIC GROWTH AND MITIGATING MEDICAL TRAUMA AMONG IBD PATIENTS17
An Atlas Characterizing the Shared Genetic Architecture of Inflammatory Bowel Disease with Clinical and Behavioral Traits17
THE ROLE OF ALCOHOL USE IN THE DEVELOPMENT OF CROHN’S DISEASE COMPLICATIONS: A RETROSPECTIVE ANALYSIS17
Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis17
REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN THE UNITED STATES OF AMERICA17
Reply: Plant-Based Diet Recommended for Inflammatory Bowel Disease17
MICROBIAL DRIVERS OF REGION-SPECIFIC SUSCEPTIBILITY TO CHRONIC, TNF-INDUCED INTESTINAL INFLAMMATION17
ALTERATIONS IN THE MUCOSA-ASSOCIATED MICROBIOME CONTRIBUTE TO THE SEVERITY OF INFLAMMATION IN A DSS-INDUCED COLITIS MODEL16
INFLAMMATORY BOWEL DISEASE IN THE MEDICARE POPULATION: AN ASSESSMENT OF OUTCOMES AND RISK FACTORS IN THE APPALACHIAN REGION16
Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis16
EXPLORING SYMPTOM PROFILES IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE USING LATENT CLASS ANALYSIS16
Correction to: Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn’s Disease and Ulcerative Colitis—An International Meta-Analysis16
RARE PRESENTATION OF CROHN’S DISEASE WITH ISOLATED OVARIAN INVOLVEMENT16
Capsule Endoscopy in Very Early-Onset Inflammatory Bowel Disease: Supporting the Clinician’s Role in Disease Interpretation16
Reply: On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease15
Pou2af1 Deficiency Aggravates DSS-Induced Colitis via Impaired Germinal Center Responses and Altered Gut Microbiota15
Risk Factors for Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis by Phase of Care15
Targeting NCAPD2 as a Therapeutic Strategy for Crohn’s Disease: Implications for Autophagy and Inflammation15
Enhancing the Rigor of Research on Herpes Zoster Risk in Patients with IBD Post-SARS-CoV2: Recommendations for Global and Detailed Analyses15
Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study15
Correction to: Risankizumab Is Effective for the Management of Crohn’s Disease of the Pouch15
IL-15 Promotes Inflammatory Th17 Cells in the Intestine15
Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis15
Perioperative anti-α4β7 Integrin Blockade Alters Wound Cell Infiltrate but Not the Functional Outcome of Ileocecal Anastomoses in Mice With Crohn’s-like Ileitis15
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease15
QUANTITATIVE AND EXPLAINABLE ARTIFICIAL INTELLIGENCE (AI)-POWERED APPROACHES TO PREDICT ULCERATIVE COLITIS DISEASE ACTIVITY FROM HEMATOXYLIN AND EOSIN (H&E)-STAINED WHOLE SLIDE IMAGES (WSI)14
Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years14
INDIGO NATURALIS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE REFRACTORY TO ADVANCED IMMUNOSUPPRESSIVE THERAPY14
Implementation of a Capillary Blood Self-Sampling Technique at Home for Monitoring of Patients With IBD14
Association of Spondyloarthritis With Chronic Opioid Use in Inflammatory Bowel Disease: A Nationwide Danish Cohort Study14
Deep Sequencing of Crohn’s Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression14
IBD GENETIC VARIATION CONTROLS T CELL EXPRESSION AND FUNCTION14
The Role of Appendicectomy in Ulcerative Colitis: Systematic Review and Meta-Analysis14
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis14
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease14
Estrogen Receptor β Activation Mitigates Colitis-associated Intestinal Fibrosis via Inhibition of TGF-β/Smad and TLR4/MyD88/NF-κB Signaling Pathways14
Preterm Birth and in Utero Exposure to Corticosteroids Are Associated With Increased Infection Risk in Children of Mothers With IBD14
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program14
Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact?14
Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn’s Disease and Ulcerative Colitis—An International Meta-Analysis14
Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn’s Disease14
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study14
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics14
IMPACT OF MULTI-MINERAL INTERVENTION ON THE PROTEOME OF HUMAN COLON ORGANOIDS UNDER PRO- AND ANTI-INFLAMMATORY CONDITIONS14
Single-cell Expression Atlas Reveals Cell Heterogeneity in the Creeping Fat of Crohn’s Disease13
Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials13
Letter to the editor: enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis13
Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies13
TRENDS AND RELATED FACTORS OF QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE13
Chronic opioid use and the risk of infections and death in patients with inflammatory bowel disease: a nationwide cohort study based on real-world data13
Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis13
Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series13
Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study13
Management of Perianal Fistulizing Crohn’s Disease13
IRE1α-XBP1 CONTROLS GROUP 3 INNATE LYMPHOID CELLS IN INFLAMMATORY BOWEL DISEASE13
SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES13
Plant-Based Diet Recommended for Inflammatory Bowel Disease13
Dynamic changes in clinical response to corticosteroids in ulcerative colitis13
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease13
Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT313
ANALYSIS OF THE GENETIC EXPRESSION OF COLON CANCER GENETIC BIOMARKERS ON INFLAMMATORY BOWEL DISEASE ON BLOOD AND BIOPSY SAMPLES13
REAL-WORLD EXPERIENCE WITH TOFACITINIB DOSE DE-ESCALATION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS13
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease12
MISSED OPPORTUNITIES FOR PREVENTING COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN AN URBAN SAFETY-NET HEALTH SYSTEM: CASE SERIES12
RACIAL DISPARITIES IN CLINICAL OUTCOMES OF PATIENTS HOSPITALIZED WITH ULCERATIVE COLITIS: INSIGHTS FROM A LARGE NATIONAL DATASET12
STERILE NEUTROPHILIA INDUCED VIA CXCR4 ANTAGONISM MITIGATES COLONIC INFLAMMATION BY ENHANCING IMMUNOSUPPRESSIVE REGULATORY T CELLS IN MICE12
BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB12
Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance12
Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update12
INFLAMMATORY BOWEL DISEASES AND RISKS OF GENITOURINARY CANCERS: A SYSTEMIC REVIEW AND META-ANALYSIS12
BACTERIAL CROSS FEEDING: EXPLORING EFFECTS OF R. GNAVUS RELEASED MUCUS CARBOHYDRATE SUBSTRATES ON ADHERENT-INVASIVE E. COLI LF82 GROWTH AND EXPRESSION OF RELEVANT MOLECULAR PATHWAYS IN AEROBIC AND ANA12
PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN’S DISEASE ON ANTI-TNF INHIBITOR THERAPY12
FIBROBLAST MICROBIAL SENSING PLAYS A CRUCIAL ROLE IN MACROPHAGE-MEDIATED HOST DEFENSE AND PREDISPOSES TO IBD-RELEVANT COLITIS12
Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease12
Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic Review12
Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn’s Disease12
Reply to “Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination”12
INFLIXIMAB AND VEDOLIZUMAB HAVE SIMILAR CLINICAL AND SAFETY OUTCOMES AMONG BIOLOGIC-NAÏVE PATIENTS WITH MILD TO MODERATE PEDIATRIC INFLAMMATORY BOWEL DISEASE12
DETERMINING ADHERENCE TO TREAT-TO-TARGET GOALS IN INFLAMMATORY BOWEL DISEASE: INSIGHTS FROM IBD QORUS SURVEY DATA12
SIMPLIFIED INDEX FOR ASSESSING MICROBIAL DIVERSITY OF THE HUMAN DIGESTIVE TRACT IN A CLINICAL SETTING12
Dysplasia detection using high-definition scopes with dye vs virtual chromoendoscopy in IBD: A meta-analysis of randomized clinical trials12
Resolving Loss of Response to Ustekinumab in Crohn’s Disease: POWER Through or Switch Treatment?11
Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation11
Penetrating ileocolic Crohn disease with intra-abdominal abscess: diagnose, drugs, drain, divert?11
A NOVEL GUT-RESTRICTED ARYL HYDROCARBON RECEPTOR AGONIST WITH ACTIVITY IN THE DEXTRAN SODIUM SULFATE COLITIS MURINE MODEL11
The Dual Role of ACE2 in IBD: Balancing SARS-CoV-2 Susceptibility and Gut Homeostasis11
Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or VariantHLADQA1*05G>A11
Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts11
In Memoriam Kim Isaacs11
NAD+ DEPLETION IN THE INTESTINAL EPITHELIUM RESULTS IN MITOCHONDRIAL DYSFUNCTION AND INFLUENCES THE PATHOGENESIS OF EXPERIMENTAL COLITIS11
Integrating the Patient Perspective to Validate a Measure of Disease Severity in Inflammatory Bowel Disease: Online Survey of Patients and Their Physicians11
ACCELERATED INPATIENT INFLIXIMAB INDUCTION FOR PATIENTS HOSPITALIZED WITH ULCERATIVE COLITIS REDUCES RISK OF COLECTOMY AT 2 YEARS COMPARED TO STANDARD INDUCTION11
Safety and Effectiveness of QingDai ( Indigo naturalis ) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial11
Patient-Specific Regulatory Network Rewiring in Inflammatory Bowel Disease: How Genetic Polymorphisms Divert Incoming Signals and Contribute to Disease Pathogenesis11
Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease11
SPH3127 (Sitokiren), a Novel Renin Inhibitor, Suppresses Colitis Development in Mouse Models of Experimental Colitis11
Shedding New Light on High-Risk Phenotypes for Pouchitis11
0.094072103500366